Under construction – not a live service
Sign in
Not yet taking people in FranceNo phase

Evolution of the Treatment of Rare Hypersomnias in a Reference Center Certified Since 2005

Key facts

Where
Paris, FranceSee the site

Where in France

  • Sleep and Vigilance Center, Hôtel-DieuParis, FranceContact: Alexandre ROUENNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Assistance Publique - Hôpitaux de Paris
Trial code
NCT07930728
Record updated
12 November 2026
Original description
Central hypersomnias are rare diseases that include narcolepsy and idiopathic hypersomnia.Read full original descriptionShow less

Central hypersomnias are rare diseases that include narcolepsy and idiopathic hypersomnia.

The Sleep and Vigilance Center at Hôtel-Dieu has been certified as a Rare Disease Reference Center (CRMR) for these conditions since 2005.

Scientific advances and changes to the ICSD (International Classification of Sleep Disorders) since 2005 (diagnostic criteria and drugs brought to market) have greatly improved the care of patients with central hypersomnia.

This retrospective and prospective study aims to evaluate how each advance translates into concrete terms in the care of patients followed at our center.

Main objective :

Determine whether new treatments are prescribed to replace treatments already on the market (reduction in prescriptions for treatments previously marketed) or whether they enable patients who have reached a therapeutic impasse to be treated (no reduction in prescriptions for treatments previously marketed).

Inclusion: Patients who have had at least one consultation or examination at the Sleep and Vigilance Center at Hôtel-Dieu since January 1, 2005; Patients diagnosed with narcolepsy (type 1 or type 2) or idiopathic hypersomnia; Adult patients (aged 18 or over); Patients who have not objected to the processing of their data.

Exclusion: Minors; Patients who object to the processing of their data; Patients under guardianship or conservatorship.

ClinicalTrials.gov NCT07930728